Viridian Therapeutics, Inc. ((VRDN)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Viridian Therapeutics, Inc. is conducting a clinical study titled A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED). The study aims to evaluate the safety and tolerability of VRDN-003, a potential treatment for TED, a condition that affects the eyes of people with thyroid disorders. This study is significant as it could lead to a new therapeutic option for TED patients.
The intervention being tested is VRDN-003, a humanized monoclonal antibody targeting the Insulin-like Growth Factor-1 receptor (IGF-1R). It is administered subcutaneously and is designed to alleviate symptoms of Thyroid Eye Disease.
The study is interventional, with a randomized, parallel assignment model. It involves triple masking, meaning the participant, investigator, and outcomes assessor are unaware of the group assignments. The primary purpose of the study is treatment-focused.
The study began on January 27, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 8, 2025, indicating ongoing recruitment and progress.
This update could positively influence Viridian Therapeutics’ stock performance by enhancing investor confidence in the potential success of VRDN-003. The study’s progress is crucial for the company, especially in the competitive landscape of TED treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.